在类风湿性关节炎中,甲状腺功能低下和自身免疫性甲状腺疾病:与疾病活动的关系
Gülseren Demir Karakiliç1, Pinar Borman2, Seher Kocaoğlu3
11Department of Physical Medicine and Rehabilitation, Yozgat City Hospital, Yozgat, Turkey.
概括
这项研究发现,虽然类风湿性关节炎 (RA) 患者中甲状腺功能低下的发病率并不高,但自身免疫性甲状腺疾病很常见. 在RA中甲状腺自身抗体与疾病活性相关,这表明甲状腺健康和RA进展之间存在联系.
科学领域:
- 类风湿病学 类风湿病学
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 在类风湿性关节炎 (RA) 中观察到甲状腺功能障碍和自身抗体,但对它们之间的关系缺乏广泛的研究.
- 以前的研究表明甲状腺自身抗体与RA疾病活性之间存在联系,但强有力的证据有限.
研究的目的:
- 为了确定RA患者甲状腺功能低下的频率.
- 调查甲状腺激素水平,自身抗体和RA疾病活动之间的关联.
主要方法:
- 一项涉及1017名RA患者的观察性研究.
- 评估的人口数据,自身抗体 (ANA,抗CCP,RF,抗TPO,抗TG),甲状腺功能 (TSH,T3,T4) 和疾病活动标志物 (CRP,ESR,DAS-28).
主要成果:
- 甲状腺功能低下影响了9.7%的患者,甲状腺功能过高影响了6%的患者.
- 甲状腺自身抗体 (抗TPO,抗TG) 在16-21%的RA患者中呈阳性.
- 在抗TG阳性患者中,在抗TPO和抗CCP之间,以及甲状腺激素,CRP和DAS-28之间发现了积极的相关性.
结论:
- 在RA患者中,自身免疫性甲状腺疾病很普遍,尽管甲状腺功能低下的发病率很低.
- 甲状腺自身抗体可能与RA疾病活性有关,需要进一步调查.
相关概念视频
Autoimmune Disorders
439
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
439
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


